SAN DIEGO, Jan. 20, 2016 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed in Florida on behalf of certain purchasers of shares of ERBA Diagnostics Inc (NYSEMKT:ERB) over alleged Securities Laws Violations by ERBA Diagnostics.
Investors who purchased shares of ERBA Diagnostics Inc (NYSEMKT:ERB) have certain options and for certain investors are short and strict deadlines running. Deadline: February 1, 2016. (NYSEMKT:ERB) investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554.
The plaintiff claims that defendants made certain allegedly false and/or misleading statements and/or allegedly failed to disclose that ERBA Diagnostics Inc lacked adequate controls over financial reporting, that ERBA Diagnostics Inc’s financial statements between April 14, 2014 and November 23, 2015 were materially false and misleading, and that as a result of the foregoing, Defendants’ statements regarding ERBA’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On November 20, 2015, ERBA Diagnostics Inc announced that the Audit Committee of the Company's Board of Directors concluded that the Company's financial statements for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 should no longer be relied upon. In addition, ERBA Diagnostics Inc stated that the Company intends to restate its financial statements for each of the years ended December 31, 2014 and 2013 and for each of the interim periods ended March 31, 2015 and June 30, 2015 by filing amendments to its Annual Report on Form 10-K for the year ended December 31, 2014, which will also include details regarding adjustments in the portion of the Non-Reliance Period occurring during the year ended December 31, 2013, and its Quarterly Reports for the periods ended March 31, 2015 and June 30, 2015 as soon as practicable.
Those who purchased ERBA Diagnostics Inc (NYSEMKT:ERB) shares have certain options and should contact the Shareholders Foundation, Inc. by e-mail at [email protected] or call +1 (858) 779-1554.
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108


Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Trump Sues BBC for Defamation Over Edited Capitol Riot Speech Clip
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Shell M&A Chief Exits After BP Takeover Proposal Rejected
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 



